Finance

Lists
S2P:FRA
Simcere Pharmaceutical Group Ltd
€1.22
-7.58%
(-0.10) 1D
Sep 10, 8:05:51 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for S2P...
Open
€1.22
High
€1.22
Low
€1.22
Mkt. cap
28.82B
Avg. vol.
68.00
Volume
0.00
52-wk high
€1.58
52-wk low
€1.00
No. of employees
7K
Open
€1.22
High
€1.22
Low
€1.22
Mkt. cap
28.82B
Avg. vol.
68.00
Volume
0.00
52-wk high
€1.58
52-wk low
€1.00
No. of employees
7K
Profile
Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration to manufacture and sell over 210 other products. Wikipedia
About Simcere Pharmaceutical Group Ltd
CEORen Jinsheng
Employees7.06K
Founded1995
HeadquartersNanjing, Jiangsu, China
SectorPharmaceutical industry
Previous reports
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.07B
2.07B
2.29B
2.29B
Cost of goods sold
365.25M
365.25M
382.55M
382.55M
Cost of revenue
365.25M
365.25M
382.55M
382.55M
Research and development expenses
465.30M
465.30M
412.46M
412.46M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
949.52M
949.52M
1.01B
1.01B
Operating expense
1.36B
1.36B
1.39B
1.39B
Total operating expenses
1.72B
1.72B
1.77B
1.77B
Operating income
351.33M
351.33M
520.99M
520.99M
Other non operating income
-
-
-
-
EBT including unusual items
425.92M
425.92M
483.36M
483.36M
EBT excluding unusual items
348.89M
348.89M
531.61M
531.61M
Income tax expense
55.72M
55.72M
70.09M
70.09M
Effective tax rate
13.08%
13.08%
14.50%
14.50%
Other operating expenses
-56.27M
-56.27M
-42.94M
-42.94M
Net income
370.20M
370.20M
414.36M
414.36M
Net profit margin
17.86%
17.86%
18.09%
18.09%
Earnings per share
-
-
-
-
Interest and investment income
14.60M
14.60M
24.20M
24.20M
Interest expense
-23.63M
-23.63M
-24.61M
-24.61M
Net interest expenses
-9.03M
-9.03M
-416.00K
-416.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
449.72M
449.72M
596.49M
596.49M
Gain or loss from assets sale
-115.50K
-115.50K
-
-
AI content may include mistakes. Learn more
Google apps